Clinical Trials with a Polyvalent Breast Cancer Vaccine.
Abstract
We have identified MUC1 and KSA as the dominant cell surface proteins or glycoproteins on most breast and ovarian cancers, and conjugation of antigens to keyhole limpet hemocyanin and mixture with the immunological adjuvant QS2l as the optimal approach to immunization. Conjugate KSA vaccines have not yet been tested in humans. We have recently prepared KSA vaccines with KSA of baculovirus origin conjugated to KLH and unconjugated. The protocol for the use of these KSA vaccines in ovarian cancer patients has been IRB, FDA and tentatively DAMD approved. Patient accrual will begin over the next month. MUCl 32 (amino acid) conjugate vaccines have induced high titer antibodies against the immunizing peptide in breast cancer patients, but only low titer antibodies against MUC1 positive tumor cells and no T-cell immunity against these cells. For induction of more relevant immune responses, longer MUC1 peptides may be required as immunogens and these peptides may need to be glycosylated. We have constructed a 106 amino acid MUC1 peptide which is currently being glycosylated for vaccine preparation. A protocol for the use of 106 aa MUC1 (glycosylated or not) conjugated to KLH for use in breast cancer patients is begin written.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1998
- Accession Number
- ADA369265
Entities
People
- Philip O. Livingston
Organizations
- Memorial Sloan Kettering Cancer Center